{"url_path":"/sec/anip/10-k/2026/item-5","section_key":"item-5","section_title":"Item 5 Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-02-27","source_url":"https://www.sec.gov/Archives/edgar/data/1023024/0001023024-26-000014-index.html","accession_number":"0001023024-26-000014","cik":"0001023024","ticker":"ANIP","issuer_name":"ANI PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1023024/0001023024-26-000014-index.html","primary_entity_key":"0001023024","primary_entity_name":"ANI PHARMACEUTICALS INC"},"word_count":442,"has_tables":true,"body_markdown":"Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities\n\nMarket Information\n\nOur common stock trades on The Nasdaq Global Market under the symbol “ANIP.”\n\nStockholder Information\n\nAs of February 20, 2026, there were approximately 360 shareholders of record of our common stock, which does not include stockholders that beneficially own shares held in a “nominee” or in “street” name, and six holders of record of Class C special stock.\n\nDividends\n\nWe have never declared or paid cash dividends on our common stock. We do not anticipate paying any cash dividends on our common stock in the foreseeable future.\n\nOur shares of Series A Convertible Preferred Stock (the “PIPE Shares”) accrued dividends at 6.50% per year on a cumulative basis, payable in cash or in-kind, and also participated, on a pro-rata basis, in any dividends that would have been declared with respect to our common stock. We paid all PIPE Share dividends in cash. There were no shares of PIPE Shares outstanding as of December 31, 2025 as all of the PIPE Shares were converted to common shares during the third quarter of fiscal 2025, as the conditions for the conversion had been satisfied.\n\nThere were also approximately 11,000 shares of Class C special stock issued and outstanding as of December 31, 2025. Holders of class C special stock are not entitled to receive dividends or to participate in the distribution of our assets upon liquidation, dissolution, or winding-up the Company.\n\nWe currently intend to retain all remaining available funds and any future earnings to fund the development and growth of our business.\n\nRecent Sales of Unregistered Securities\n\nNone.\n\nIssuer Purchases of Equity Securities\n\nPeriod\nTotal Number\n\nof Shares\n\nPurchased(1)\nAverage Price\nPaid per ShareTotal Number of\nShares Purchased as\nPart of Publicly\nAnnounced Plans or\nProgramsMaximum Number (or\napproximate dollar\nvalue) of Shares\n that may yet be\nPurchased Under the\nPlans or Programs\n\nOctober 1 - October 31, 2025—$— —$— \n\nNovember 1 - November 30, 20255,730$84.02 —$— \n\nDecember 1 - December 31, 20251,594$81.51 —$— \n\nTotal7,324$83.47 —\n\n(1)Shares purchased during the period were transferred to the Company from employees in satisfaction of minimum tax withholding obligations associated with the vesting of restricted stock awards during the period.\n\n59\n\n[Table of Contents](#id93db5ee702e4e9d8da25580f80f13e1_7)\n\nPerformance Graph\n\nThe graph below compares the five-year cumulative total stockholder return on our common stock, the Nasdaq Stock Market (US) Index, and the S&P 600 Pharmaceuticals, Biotechnology & Life Sciences Index, assuming the investment of $100.00 on December 31, 2020, with dividends being reinvested. The stock price performance in the graph below is not necessarily indicative of future price performance.\n\n60\n\n[Table of Contents](#id93db5ee702e4e9d8da25580f80f13e1_7)"}